Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M923 vs Humira in Moderate to Severe Chronic Plaque Psoriasis
NCT02581345Phase 3Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of BAX 2923 in plaque psoriasis, sponsored by Momenta Pharmaceuticals. Started Sep 2015; status: completed.
02
Drugs
BAX 2923
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02581345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581345.